Clinical response in patients with relapsed centroblastic centrocytic non-Hodgkin's lymphoma after treatment with anti-CD20 antibody IDEC C2B8 (MabThera)
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2014
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 05 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
- 23 Mar 2008 Status changed from in progress to completed, from Roche record.
- 09 Jun 2006 New trial record.